Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 35
2000 57
2001 163
2002 213
2003 197
2004 315
2005 380
2006 279
2007 175
2008 99
2009 79
2010 65
2011 49
2012 42
2013 38
2014 23
2015 32
2016 22
2017 37
2018 28
2019 18
2020 16
2021 21
2022 15
2023 15
2024 13
2025 17
2026 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,318 results

Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
COX-1 and COX-2 inhibitors.
Hawkey CJ. Hawkey CJ. Best Pract Res Clin Gastroenterol. 2001 Oct;15(5):801-20. doi: 10.1053/bega.2001.0236. Best Pract Res Clin Gastroenterol. 2001. PMID: 11566042 Review.
Truly selective COX-2 inhibitors have been shown to have no effect on gastric mucosal prostaglandin synthesis, to cause no acute injury, and no chronic ulceration compared to placebo. ...The VIGOR study has raised the possibility that some NSAIDs, particularly na
Truly selective COX-2 inhibitors have been shown to have no effect on gastric mucosal prostaglandin synthesis, to cause no acute inju …
Rofecoxib.
Scott LJ, Lamb HM. Scott LJ, et al. Drugs. 1999 Sep;58(3):499-505; discussion 506-7. doi: 10.2165/00003495-199958030-00016. Drugs. 1999. PMID: 10493277 Review.
Rofecoxib selectively inhibits cyclo-oxygenase-2 in a dose-dependent manner in humans. No significant inhibition of cyclo-oxygenase-1 is observed with rofecoxib up to doses of 1000 mg. ...Rofecoxib is also an effective analgesic in patients with primar
Rofecoxib selectively inhibits cyclo-oxygenase-2 in a dose-dependent manner in humans. No significant inhibition of cyclo-oxygenase-1
Rofecoxib.
Hillson JL, Furst DE. Hillson JL, et al. Expert Opin Pharmacother. 2000 Jul;1(5):1053-66. doi: 10.1517/14656566.1.5.1053. Expert Opin Pharmacother. 2000. PMID: 11249495 Review.
Rofecoxib (Vioxx, Merck & Co., Inc.) is a new orally-effective non-steroidal anti-inflammatory drug (NSAID) approved for treatment of acute pain, fever, primary dysmenorrhea and pain and inflammation in osteoarthritis (OA). ...As cells in the gastrointestinal (G
Rofecoxib (Vioxx, Merck & Co., Inc.) is a new orally-effective non-steroidal anti-inflammatory drug (NSAID) approved for t
Rofecoxib for osteoarthritis.
Garner SE, Fidan DD, Frankish R, Maxwell L. Garner SE, et al. Cochrane Database Syst Rev. 2005 Jan 25;2005(1):CD005115. doi: 10.1002/14651858.CD005115. Cochrane Database Syst Rev. 2005. PMID: 15654705 Free PMC article.
Comparable trials were pooled using fixed effects model. MAIN RESULTS: Twenty-six RCTs were included. The comparators were placebo, diclofenac, ibuprofen, naproxen, nimesulide, nabumetone, paracetamol, celecoxib and Arthrotec. The evidence reviewed indicated …
Comparable trials were pooled using fixed effects model. MAIN RESULTS: Twenty-six RCTs were included. The comparators were placebo
Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial.
Aisen PS, Schafer KA, Grundman M, Pfeiffer E, Sano M, Davis KL, Farlow MR, Jin S, Thomas RG, Thal LJ; Alzheimer's Disease Cooperative Study. Aisen PS, et al. JAMA. 2003 Jun 4;289(21):2819-26. doi: 10.1001/jama.289.21.2819. JAMA. 2003. PMID: 12783912 Clinical Trial.
CONTEXT: Laboratory evidence that inflammatory mechanisms contribute to neuronal injury in Alzheimer disease (AD), along with epidemiological evidence, suggests that nonsteroidal anti-inflammatory drugs (NSAIDs) may favorably influence the course of the disease
CONTEXT: Laboratory evidence that inflammatory mechanisms contribute to neuronal injury in Alzheimer disease (AD), along with …
Cyclooxygenase-2 inhibitors.
Hawkey CJ, Fortun PJ. Hawkey CJ, et al. Curr Opin Gastroenterol. 2005 Nov;21(6):660-4. doi: 10.1097/01.mog.0000182860.11669.04. Curr Opin Gastroenterol. 2005. PMID: 16220041 Review.
Some, but not all, studies have suggested increased myocardial infarction with certain cyclooxygenase-2 inhibitors, in particular rofecoxib. It is unclear whether this is a class effect because there are inconclusive data to incriminate celecoxib despite a relativel …
Some, but not all, studies have suggested increased myocardial infarction with certain cyclooxygenase-2 inhibitors, in particular rofecox
Rofecoxib in migraine.
Krymchantowski AV, Bigal ME. Krymchantowski AV, et al. Expert Rev Neurother. 2005 Jan;5(1):55-61. doi: 10.1586/14737175.5.1.55. Expert Rev Neurother. 2005. PMID: 15853474 Review.
Among the available drugs, nonsteroidal anti-inflammatory drugs still represent effective options and a new class of nonsteroidal anti-inflammatory drugs known as selective cyclooxygenase-2 inhibitors may represent an even better-tolerated therapy with regard to gastrointe …
Among the available drugs, nonsteroidal anti-inflammatory drugs still represent effective options and a new class of nonsteroidal ant …
Aspirin and other non-steroidal anti-inflammatory drugs for the prevention of dementia.
Jordan F, Quinn TJ, McGuinness B, Passmore P, Kelly JP, Tudur Smith C, Murphy K, Devane D. Jordan F, et al. Cochrane Database Syst Rev. 2020 Apr 30;4(4):CD011459. doi: 10.1002/14651858.CD011459.pub2. Cochrane Database Syst Rev. 2020. PMID: 32352165 Free PMC article.
One trial (2528 participants) investigated the cyclo-oxygenase-2 (COX-2) inhibitor celecoxib (200 mg twice daily) and the non-selective NSAID naproxen (220 mg twice daily) for preventing dementia in cognitively healthy older adults with a family history of Alzheimer
One trial (2528 participants) investigated the cyclo-oxygenase-2 (COX-2) inhibitor celecoxib (200 mg twice daily) and the non-selective NSAI …
The safety of rofecoxib.
Burnier M. Burnier M. Expert Opin Drug Saf. 2005 May;4(3):491-9. doi: 10.1517/14740338.4.3.491. Expert Opin Drug Saf. 2005. PMID: 15934855 Review.
Recently, new evidence have become available indicating that rofecoxib indeed increases the number of thrombo-embolic events. These data have resulted in the complete withdrawal of rofecoxib from the market. Was it scientifically reasonable to withdraw rofecoxib
Recently, new evidence have become available indicating that rofecoxib indeed increases the number of thrombo-embolic events. These d …
COX-2 inhibitors.
Brooks PM, Day RO. Brooks PM, et al. Med J Aust. 2000 Oct 16;173(8):433-6. Med J Aust. 2000. PMID: 11090038
Two COX-2 inhibitors are currently available in Australia--celecoxib, which is taken twice daily, and rofecoxib, which is taken once daily. Both drugs act rapidly in providing pain relief and their anti-inflammatory analgesic effect in osteoarthritis and rheumatoid …
Two COX-2 inhibitors are currently available in Australia--celecoxib, which is taken twice daily, and rofecoxib, which is taken once …
2,318 results